CARLOS VIANA POYARES JARDIM

Índice h a partir de 2011
16
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2013 ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • conferenceObject
    Incident pulmonary arterial hypertension in a Brazilian reference center: Results of a four-year registry
    (2013) ALVES- JR., Jose Leonidas; GAVILANES, Francisca; JARDIM, Carlos; FERNANDES, Caio; KATO, Luciana; HOETTE, Susana; DIAS, Bruno; HOVNANIAN, Andre; SOUZA, Rogerio
  • conferenceObject
    The role of right heart catheterization prior to initiation of PAH specific therapy
    (2013) GAVILANES, Francisca; ALVES- JR., Jose Leonidas; FERNANDES, Caio; JARDIM, Carlos; KATO, Luciana; HOETTE, Susana; HOVNANIAN, Andre; DIAS, Bruno; SOUZA, Rogerio
  • conferenceObject
    Chronotropic response during exercise in schistosomiasis associated PAH as compared to idiopathic PAH
    (2013) MORINAGA, Luciana; ALBUQUERQUE, Andre; JARDIM, Carlos; FERNANDES, Caio; BREDA, Ana Paula; HOETTE, Susana; SOUZA, Rogerio
  • article 11 Citação(ões) na Scopus
    Idiopathic Pulmonary Arterial Hypertension
    (2013) SOUZA, Rogerio; JARDIM, Carlos; HUMBERT, Marc
    Idiopathic pulmonary arterial hypertension (IPAH), formerly called primary pulmonary hypertension, is a rare disease (incidence and prevalence rates of approximately one and six cases per million inhabitants, respectively) with different clinical phenotypes. A group of diverse conditions manifest pulmonary arterial hypertension (PAH) and share similar pathological and/or clinical findings with IPAH. By definition, IPAH is diagnosed only after alternative diagnoses have been ruled out. Extensive investigation is needed to determine if PAH is associated with thyroid diseases, infectious diseases, autoimmune conditions, exposure to certain drugs (particularly anorexigens), certain genetic mutations, and so on. The presence of genetic abnormalities and risk factors (such as specific drug exposures) reinforces the ""multiple hit"" concept for the development of pulmonary hypertension. Fortunately, within the past two decades, therapeutic options have become available for IPAH, resulting in improved survival and clinical outcomes. At least seven different compounds have been registered for PAH treatment. However, even with aggressive PAH-specific therapy, mortality rates remain high (similar to 40% at 5 years). Given the high mortality rates, the use of combinations of agents that work by different pathways has been advocated (either as ""add-on"" therapy or initial ""up front"" therapy). Further, new therapeutic agents and treatment strategies are on the near horizon, aiming to further improve survival from the remarkable progress already seen.